Risk of Second Primary Cancer and Death Following a Diagnosis of Nonmelanoma Skin Cancer
- 1Department of Epidemiology and Cancer Registry, 2Department of Internal Medicine, Section of Dermatology, Section of Hematology and Oncology, CancerCare Manitoba; 3Department of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; 4Medical Oncology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada; and 5School of Public Health, The University of Sydney, Sydney, Australia
- Requests for reprints:
Alain Demers, CancerCare Manitoba, Epidemiology and Cancer Registry, 675 McDermot Avenue, Winnipeg, Manitoba, Canada, R3E 0V9. Phone: 204-787-2146; Fax: 204-786-0628. E-mail: alain.demers{at}cancercare.mb.ca
Abstract
Cancer-free patients diagnosed with a first primary nonmelanoma skin cancer (NMSC) offer an opportunity for studying the risk of a second primary cancer without the confounding effect of systemic treatment. The objective of the study was to estimate the risk of second primary cancer in people with a history of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) and the risk of dying in cancer patients with a NMSC history. BCC and SCC cases diagnosed between 1956 and 2000 in Manitoba, Canada were followed-up for second primaries (other than NMSC). Standardized incidence and mortality ratios (SIR and SMR) were calculated. Men [SIR, 1.06; 95% confidence interval (95% CI), 1.02-1.10] and women (SIR, 1.07; 95% CI, 1.02-1.12) with a BCC history as well as men (SIR, 1.15; 95% CI, 1.08-1.22) with a SCC history were at greater risk of a second primary cancer. Overall, the increased risk was observed only in the first 4 years following a NMSC, although it remained increased for specific cancer sites. The risk remained higher in all age groups up to 75 years of age. People with a history of BCC (males: SMR, 1.09; 95% CI, 1.04-1.14; females: SMR, 1.24; 95% CI, 1.16-1.32) or SCC (males: SMR, 1.18; 95% CI, 1.09-1.27; females: SMR, 1.55; 95% CI, 1.35-1.79) had a greater risk of death following their second primaries. Even if NMSC patients are at greater risk of a second cancer, it is not recommended to follow them up beyond the generally accepted periodic examination of the skin.
Footnotes
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted August 29, 2005.
- Received May 25, 2005.
- Revision received August 10, 2005.
